Janux Therapeutics, Inc. cotiza a 18.15 USD y tiene una capitalización bursátil de $1.1B. En los últimos 12 meses ha facturado $24M con un margen de flujo de caja libre del -832.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates in…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.35 | $-0.39 | $-0.51 |
| Estimado | $-0.49 | $-0.29 | $-0.52 | $-0.64 |
| Sorpresa | — | -20.7% | +25.0% | +20.3% |
| Métrica | JANX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1576.7% | -38.6% | -1538.1% |
| Net Margin | -1136.3% | -33.6% | -1102.7% |
| FCF Margin | -832.8% | -13.9% | -818.9% |
| ROE | -11.9% | -40.4% | +28.5% |
| ROA | -11.3% | -32.0% | +20.7% |
| Current Ratio | 39.04 | 2.84 | +36.20 |
| Debt / Equity | — | 0.28 | — |